Actelion Ltd., the Swiss drugmaker that gets almost 90 percent of sales from a treatment for a rare lung disease, said Andre Muller will replace Chief Financial Officer Andrew Oakley, who is leaving the company.
Muller, 49, will start the position on Sept. 1, the Allschwil-based company said in a statement today. Oakley, 51, is leaving to “focus on opportunities outside Actelion,” the drugmaker said.
Muller is moving from Pierre Fabre SA, a maker of pharmaceuticals and cosmetics, where he held the same position. Oakley has been CFO of Actelion for 10 years.
Actelion raised its full-year profit forecast in July as second-quarter sales beat estimates and it cut spending. The improved outlook may renew takeover speculation, Andrew Weiss, an analyst at Bank Vontobel AG in Zurich, said at the time.